1. Home
  2. AVTE

AVTE

Aerovate Therapeutics Inc.

Logo Aerovate Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 3:58pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.

Founded: 2018 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 703.3M IPO Year: 2021
Target Price: $50.00 AVG Volume (30 days): 148.4K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.87 EPS Growth: N/A
52 Week Low/High: $9.41 - $32.42 Next Earning Date: 05-13-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: